For all the sense of anticipation about US Food and Drug Administration-approved products possibly being used in a European patient population for the first time, the Swiss medtech industry and market have one overriding priority: to work closely with the EU regulatory system and perhaps one day re-establish the mutual recognition agreement (MRA) with the EU.
The MRA effectively came to an end for the respective Swiss and EU medtech industries on 26 May 2021, after the Swiss Federal Council officially broke off institutional agreement negotiations...